Sophie Cousin, MD, Institut Bergonié, Bordeaux, France, describes an analysis of two precision medicine studies, BIP (NCT02534649) and STING (NCT04932525) aiming to assess the prognostic impact of tumor fraction (TF) in patients with advanced solid tumors considered for early phase trials. The two independent precision medicine studies enrolled 1912 consecutive patients. TF, measured from comprehensive genomic profiling, was analyzed as a binary variable. High TF was associated with significantly worse overall-survival (OS) in both studies. Multivariate analysis confirmed that TF independently predicted worse OS, regardless of other validated prognostic scores. This prospective analysis highlights TF as a strong prognostic factor in advanced solid tumors and emphasizes its potential usefulness in patient selection for phase I trial entry. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
